Stock fact sheet · data as of
Mesa Laboratories, Inc. (MLAB): fair value, margin of safety and Wheel Score
Healthcare · Medical - Specialties · United States · Blend
Is MLAB undervalued?
At 127.74 (close of 16 Oct 2026), MLAB trades 182% over the GLS average fair value of 45.24, with 1 of 9 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
The 9 models disagree widely: Lynch gives 5.77 while 10 Cap gives 211.82. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files MLAB under Blend.
Nine valuation models for MLAB
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 6.62 | -95% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 25.24 | -80% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 18.35 | -86% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 5.77 | -95% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 42.16 | -67% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 211.82 | +66% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 78.36 | -39% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | 9.42 | -93% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 9.43 | -93% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -24.17 | -119% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 110.00 | -14% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
On financial health MLAB scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is low at 3.3 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC 1.9%, ROE 3.6%, ROA 1.6% - with debt at 0.91 times equity and a free-cash-flow yield of 7.9%.
The dividend yield is 0.50% with a payout ratio of 74% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Sterilization and Disinfection Control 41%, Calibration Solutions 22%, Biopharmaceutical Development 20% (quarter Q1 FY2027).
Institutional ownership scores 10/10, insider activity 6/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 1.9% |
|---|---|---|---|
| GLS Moat | 3.3 / 10 | ROE | 3.6% |
| Debt / equity | 0.91 | ROA | 1.6% |
| Free-cash-flow yield | 7.9% | Payout ratio | 74% |
| Institutions | 10 / 10 | Insiders · Congress | 6 · 5 / 10 |
Wheel Score 28: No options
MLAB has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (28 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 100k shares a day on a market cap of $715M, with a beta of 1.05; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -182% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 5 / 15 | moat 3.3/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 7 / 20 | 100k shares/day, $715M cap, beta 1.05 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026 (after the close), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium. The next ex-dividend date is 30 Nov 2026 (0.1600 per share).
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Specialties
The 12 companies below are the closest to Mesa Laboratories, Inc. by market cap within the Medical - Specialties industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| QDEL QuidelOrtho Corporation | 13.87 | - | - | 45Weak | $951M |
| MASS 908 Devices Inc. | 11.89 | 0.2993 | -3872% | 32Weak | $491M |
| BWAY BrainsWay Ltd. | 11.82 | 8.13 | -45% | 33Weak | $464M |
| SI Shoulder Innovations, Inc. | 17.87 | - | - | 26No options | $372M |
| ANIK Anika Therapeutics, Inc. | 20.69 | 2.47 | -737% | 40Weak | $277M |
| MOBI Mobia Medical, Inc. Common Stock | 8.31 | - | - | 22No options | $277M |
| LAB Standard BioTools Inc. | 0.6584 | - | - | 36Weak | $258M |
| TRIB Trinity Biotech plc | 6.61 | - | - | 26Weak | $134M |
| NYXH Nyxoah S.A. | 1.19 | - | - | 26No options | $121M |
| APYX Apyx Medical Corporation | 2.56 | - | - | 35Weak | $108M |
| SKIN SkinHealth Systems Inc. | 11.56 | 67.34 | +83% | 45Weak | $75M |
| DRIO DarioHealth Corp. | 5.13 | 119.64 | +96% | 39No options | $50M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about MLAB
Is MLAB undervalued right now?
No: at 127.74 the stock trades 182% above the GLS average fair value of 45.24 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of MLAB and what does it mean?
MLAB has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for MLAB?
45.24 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Mesa Laboratories, Inc. report earnings next?
The next earnings report is due on 5 Nov 2026 (after the close), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does MLAB have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on MLAB, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.